SH
Therapeutic Areas
Nurix Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bexobrutideg (NX-5948) | Relapsed/Refractory B-cell Malignancies | Phase 1a/1b |
| NX-2127 | Relapsed/Refractory B-cell Malignancies | Phase 1a |
| NX-1607 | Oncology & Autoimmune Indications | Phase 1 |
| NX-0479 | Immuno-inflammatory Diseases | Phase 1 |
| NX-0451 | Solid Tumors | Preclinical |
| NX-0370 | Solid Tumors | Preclinical |
| NX-0290 | Solid Tumors | Preclinical |